Thrombopoietin receptor agonists in immune thrombocytopenia: a comparative review of mechanisms, efficacy, and the future of personalized management

TPO-RAs now represent a cornerstone of chronic ITP management and are expected to see broader use as growing evidence supports earlier and more individualized treatment strategies. Future progress will rely on personalized therapeutic strategies, informed monitoring, and AI-driven predictive tools that together may enhance remission durability and long-term clinical outcomes.